NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
0 hedge funds and large institutions have $0 invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 74 closing their positions.
41.49% less ownership
Funds ownership: 41.49% → 0% (-41%)
100% less funds holding
Funds holding: 75 → 0 (-75)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $55.1M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 74
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Column Group
San Francisco,
California
|
-$28.8M |
| 2 |
BlackRock
New York
|
-$4.78M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.7M |
| 4 |
StepStone Group
La Jolla,
California
|
-$2.5M |
| 5 |
EC
Euclidean Capital
New York
|
-$1.58M |
NGM Hedge Fund Activity: Q2 2024 in Review
0 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2024, worth a combined $0 — down 100% from $55.1M a quarter earlier.
Sellers outnumbered buyers: 74 funds closed out of NGM and 0 opened new positions — a net loss of 74 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Column Group, exiting entirely with an estimated $28.8M sold.
- 0 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2024, down from 75 in Q1 2024.
- Funds reported $0 of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
- 0 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2024 and 74 closed out, a net change of -74 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2024 was Column Group, an estimated $28.8M sold.
Based on aggregated 13F filings for Q2 2024.